A Sydney data scientist has become the first person to use artificial intelligence to create a personalized cancer vaccine for his dog, a breakthrough that has captured the attention of the scientific community. The experimental treatment led to a 75% reduction in the dog’s tumor, offering new hope for both veterinary and human medicine.

AI and Cancer Research in Animals

Paul Conyngham, a 42-year-old data scientist and machine learning engineer, used artificial intelligence tools, including ChatGPT, to design a targeted cancer vaccine for his rescue dog, Rosie. Rosie was diagnosed with advanced mast cell cancer in 2024, and veterinary treatment had only slowed the disease’s progression without reducing the tumors.

Conyngham, who has no formal background in biology, decided to take matters into his own hands. He sequenced Rosie’s tumor DNA and healthy DNA at the University of New South Wales, spending approximately £2,350 ($3,000) on the analysis. The data was used to compare healthy cells with cancer cells and identify the genetic mutations responsible for the disease.

Using artificial intelligence tools, including AlphaFold, a protein modeling program, Conyngham developed a formula designed to target the specific mutations causing the tumor’s growth. He explained the process during a television interview, stating, ‘We took her tumour, sequenced the DNA, we converted it from tissue to data, and we used that to find the problem in her DNA and then develop a cure based off that.’

From AI to Vaccine Development

After identifying the mutations, Conyngham attempted to obtain an immunotherapy drug that could treat the cancer. A pharmaceutical company declined to provide the medication for compassionate use. As a result, he turned to the RNA Institute at the University of New South Wales to manufacture a custom mRNA vaccine based on the formula.

The vaccine aimed to train Rosie’s immune system to recognize and attack cancer cells. Less than two months after the genetic sequence was completed, Rosie received her first injection in December 2023. By mid-March, Conyngham reported a dramatic change in the dog’s condition, with the tumor on her leg shrinking by around 75%.

Rosie’s tumor had previously been described as the size of a tennis ball, and the improvement in her condition was notable. Conyngham said, ‘At the start of December her mobility was way down, she started to shut down and be a bit sad.’ He later added, ‘And towards the end of January, she was jumping over a fence to chase a rabbit.’

Significance for Future Medical Research

Researchers at the University of New South Wales have called this case the first personalized cancer vaccine created for a dog. The treatment has raised questions among scientists about how similar technology could be used for human patients.

Martin Smith, director of the UNSW Ramaciotti Centre for Genomics, said the work highlights future possibilities for medicine. He stated, ‘It raises the question, if we can do this for a dog, why aren’t we rolling this out to all humans with cancer?’ Páll Thordarson, director of the UNSW RNA Institute, also described the achievement as a sign of developing technology. He said the project shows how artificial intelligence tools could assist with medical research and treatment development.

Conyngham’s project has sparked interest in the potential of AI in personalized medicine. The use of ChatGPT and other AI tools to analyze complex genetic data and develop targeted treatments could revolutionize cancer care for both animals and humans. The success of this case has led to further research into the application of AI in veterinary medicine and its potential for human use.

As the field of personalized medicine continues to evolve, the case of Rosie and her AI-designed vaccine offers a glimpse into the future of cancer treatment. Scientists are now exploring how these technologies can be adapted for broader use, potentially leading to more effective and tailored treatments for patients with various forms of cancer.

With ongoing research and collaboration between data scientists, biologists, and medical professionals, the integration of AI into cancer treatment may become more common in the coming years. The implications of this breakthrough are significant, as it could lead to more personalized and effective treatments for both humans and animals.

The success of Rosie’s treatment has also encouraged other researchers to explore the potential of AI in medical research. The development of new tools and techniques could lead to more efficient and targeted treatments for a wide range of diseases. As the field continues to advance, the use of AI in medicine is expected to grow, offering new hope for patients with complex and difficult-to-treat conditions.